Training
Training on Pfizer‒BioNTech COVID-19 mRNA Vaccine COMIRNATY® (Tozinameran) - Updated 5 October 2021
This is a training resource for Tozinameran COVID-19 mRNA Vaccine (nucleoside modified) ‒ COMIRNATY® (Pfizer‒BioNTech) that:
1. describes what is new and different for introducing Tozinameran COVID-19 mRNA vaccine (Pfizer–BioNTech); and
2. identifies key programmatic considerations involved in introducing this vaccine.
Languages
- English
Publication year
2021
Type
Training
Categories
- Programme management
Diseases
- COVID-19
Topic references
COVAX-PFIZER